DexCom (DXCM)
(Delayed Data from NSDQ)
$72.24 USD
-1.43 (-1.94%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $72.03 -0.21 (-0.29%) 7:12 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$72.24 USD
-1.43 (-1.94%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $72.03 -0.21 (-0.29%) 7:12 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Zacks News
DexCom (DXCM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Wall Street Bulls Look Optimistic About DexCom (DXCM): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), DexCom (DXCM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter 2024 results are likely to reflect rising volumes across all channels.
Ahead of DexCom (DXCM) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Zacks Investment Ideas feature highlights: Vertiv, Align Technology and DexCom
by Zacks Equity Research
Vertiv, Align Technology and DexCom are part of the Zacks Investment Ideas article.
3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback
by Benjamin Rains
Long-term investors are often well-served to buy stocks amid bouts of weakness.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS
by Zacks Equity Research
Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.
DexCom (DXCM) Stock Moves -1.16%: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $134.56, marking a -1.16% move from the previous day.
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
by Urmimala Biswas
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.
DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management
by Zacks Equity Research
DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
Should First Trust Growth Strength ETF (FTGS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTGS
Why the Market Dipped But DexCom (DXCM) Gained Today
by Zacks Equity Research
In the most recent trading session, DexCom (DXCM) closed at $139.94, indicating a +0.73% shift from the previous trading day.
DexCom, Inc. (DXCM) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
DexCom (DXCM) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, DexCom (DXCM) stood at $136.65, denoting a -0.94% change from the preceding trading day.
Tenet (THC) Divests Six Hospitals, Sustains Divestiture Spree
by Zacks Equity Research
Tenet Healthcare (THC) completes the sale of six California hospitals, four to UCI Health and two to Adventist Health, to refine the portfolio and reduce debt burden.
DexCom (DXCM) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about DexCom's (DXCM) strong product portfolio.
DexCom (DXCM) Stock Moves -0.12%: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $139.93, marking a -0.12% move from the previous day.
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
Compelling Reasons to Hold on to UnitedHealth Group (UNH) Stock
by Zacks Equity Research
UnitedHealth Group (UNH) remains well-poised for growth on the back of improved premiums, acquisitions and partnerships, an in-demand telehealth services suite and solid cash-generating abilities.
DexCom, Inc. (DXCM) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching DexCom (DXCM) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
DexCom (DXCM) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
DexCom (DXCM) closed at $134.17 in the latest trading session, marking a -0.41% move from the prior day.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.